Featured Research
The Crohn's & Colitis Foundation collaborates with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below, and the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.
Current Results: 17 entries
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
- To evaluate the effect of the prebiotic fiber inulin on the microbiome of children with IBD who have subclinical disease activity (patients with no symptoms but elevated fecal calprotectin)
- To evaluate the efficacy of the prebiotic fiber inulin in reducing gut inflammation (fecal calprotectin) in IBD
The primary objective of this study is to evaluate whether investigational cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
The purpose of the PURSUIT 2 study is to see if an investigational medicine is safe and effective for treating children and young adults with UC.
The primary objective is to assess the efficacy of study drug on clinical remission in subjects with moderately to severely active ulcerative colitis (UC) after 12 and 52 weeks of treatment.
The purpose of this study is to compare the effects (both good and bad) of both Stelara and Humira for those that have Crohn's Disease.
Demonstrate the long-term safety and efficacy of ozanimod for the treatment of subjects with moderate to severely active CD.
The primary objective of this study is to evaluate the efficacy of oral ozanimod compared with placebo on the induction of clinical remission.
The primary objective of this study is to evaluate the efficacy of oral ozanimod compared with placebo on the induction of clinical remission.
The primary objective is to demonstrate the efficacy of ozanimod compared to placebo on the maintenance of clinical remission and endoscopic response.